• Guido Parodi and Robert F Storey.
• Department of Heart and Vessels, Careggi Hospital, Florence, Italy Post-graduate School in Cardiology, University of Florence, Italy parodiguido@gmail.com.
• Eur Heart J Acute Cardiovasc Care. 2015 Dec 1; 4 (6): 555-60.

AbstractThe occurrence of dyspnoea in acute coronary syndrome (ACS) patients has always been considered a challenging diagnostic and therapeutic clinical scenario. P2Y12 platelet receptor inhibitors (i.e., clopidogrel, prasugrel and ticagrelor) are currently the cornerstone of treatment of ACS patients. Thus, in the last few years, the potential association between ACS and dyspnoea has also become more challenging with the increasing use of ticagrelor in these patients due to its beneficial effects on ischaemic event prevention and mortality, since ticagrelor can induce dyspnoea as a side effect. The present article is intended to review the current literature regarding dyspnoea occurrence in ACS patients, especially those treated with ticagrelor, and to propose ticagrelor-associated dyspnoea management recommendations based on current knowledge. © The European Society of Cardiology 2014.

15 keywords...

hide…